Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data.

MLA

Qi, Wei-Xiang, et al. “Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data.” PLoS ONE, vol. 8, no. 2, Feb. 2013, pp. 1–9. EBSCOhost, https://doi.org/10.1371/journal.pone.0055637.

APA

Qi, W.-X., Wang, Q., Jiang, Y.-L., Sun, Y.-J., Tang, L., He, A., Min, D., Lin, F., Shen, Z., & Yao, Y. (2013). Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data. PLoS ONE, 8(2), 1–9. https://doi.org/10.1371/journal.pone.0055637

Chicago

Qi, Wei-Xiang, Qiong Wang, Yan-Ling Jiang, Yuan-Jue Sun, Li-na Tang, Ai-na He, Da-liu Min, Feng Lin, Zan Shen, and Yang Yao. 2013. “Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data.” PLoS ONE 8 (2): 1–9. doi:10.1371/journal.pone.0055637.